19 August 2022
Ropes & Gray Advises Everest Medicines on Agreement with Gilead Sciences for Cancer Drug Trodelvy in Asia Territories
Advising firms
Deal team
1 lawyer named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| not_stated | Ropes & Gray | Not stated | life sciences, corporate and tax | Shanghai, Hong Kong and Boston |
Want co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 455m ($455 million)
- What the figure measures
- Total transaction value
- Client
- Everest MedicinesSell-side
- Counterparties
- Immunomedics, Inc. (Buy-side)
Gilead Sciences (Buy-side)